TABLE 3.
Base Case Model
| Manufacturer regimen | PRN regimen | T&E regimen | RWE regimen | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US population | Health plan | PMPM | US population | Health plan | PMPM | US population | Health plan | PMPM | US population | Health plan | PMPM | |
| Without brolucizumab | ||||||||||||
| Drug cost and administration cost | ||||||||||||
| One eye | $9,750 M | $29.3 M | $2.44 | $5,851 M | $17.6 M | $1.46 | $7,470 M | $22.4 M | $1.87 | $6,571 M | $19.7 M | $1.64 |
| Fellow eye | $3,741 M | $11.2 M | $0.94 | $2,242 M | $6.7 M | $0.56 | $2,868 M | $8.6 M | $0.72 | $2,528 M | $7.6 M | $0.63 |
| Monitoring cost | ||||||||||||
| One eye | $2,005 M | $6.0 M | $0.50 | $2,119 M | $6.4 M | $0.53 | $1,552 M | $4.7 M | $0.39 | $1,306 M | $3.9 M | $0.33 |
| Fellow eye | $422 M | $1.3 M | $0.11 | $444 M | $1.3 M | $0.11 | $332 M | $1.0 M | $0.08 | $283 M | $0.9 M | $0.07 |
| Total cost | $15,917 M | $47.8 M | $3.98 | $10,656 M | $32.0 M | $2.67 | $12,221 M | $36.7 M | $3.06 | $10,687 M | $32.1 M | $2.67 |
| With brolucizumab | ||||||||||||
| Drug cost and administration cost | ||||||||||||
| One eye | $9,734 M | $29.2 M | $2.44 | $6,043 M | $18.1 M | $1.51 | $7,510 M | $22.6 M | $1.88 | $6,553 M | $19.7 M | $1.64 |
| Fellow eye | $3,735 M | $11.2 M | $0.93 | $2,317 M | $7.0 M | $0.58 | $2,884 M | $8.7 M | $0.72 | $2,521 M | $7.6 M | $0.63 |
| Monitoring cost | ||||||||||||
| One eye | $1,997 M | $6.0 M | $0.50 | $2,125 M | $6.4 M | $0.53 | $1,550 M | $4.7 M | $0.39 | $1,300 M | $3.9 M | $0.33 |
| Fellow eye | $420 M | $1.3 M | $0.11 | $445 M | $1.3 M | $0.11 | $331 M | $1.0 M | $0.08 | $282 M | $0.8 M | $0.07 |
| Total cost | $15,886 M | $47.7 M | $3.98 | $10,930 M | $32.8 M | $2.74 | $12,275 M | $36.9 M | $3.07 | $10,656 M | $32.0 M | $2.67 |
| Budget impact | −$30.99 M | −$93,068 | −$0.008 | $274.58 M | $824,696 | $0.069 | $54.30 M | $163,101 | $0.014 | −$31.35 M | −$94,170 | −$0.008 |
PMPM budget impact cost in the last row is presented to 3 decimals for accuracy of interpretation, and rest are presented up to 2 decimals. A negative value indicates a net budgetary decrease (cost saving), whereas a positive value indicates a net budgetary increase with the introduction of brolucizumab in the market.
M = million; PMPM = per member per month; PRN = pro re nata; RWE = real-world evidence; T&E= treat and extend.